View Document Preview and Link Document Date: 2014-04-24 08:24:09 Open Document File Size: 98,95 KB Share Result on Facebook
City Orlando / Titusville / / Company AEs / Gilead Sciences / Janssen Pharmaceuticals / LabCorp / / Country United States / Ireland / / Event Person Communication and Meetings / FDA Phase / / Facility National Library of Medicine / / MedicalCondition autoimmune disorders / CHC / recurrent hepatitis C / chronic HCV / cirrhosis / compensated liver disease / hepatitis C / HCV / genotype 1a infection / virus infection / hepatitis C. Available / cardiac disease / infectious diseases / hypersensitivity / infection / autoimmune hepatitis / depression / genotype 1a CHC / hepatic disease / chronic hepatitis C / HCV genotype / / MedicalTreatment Alternative therapy / liver transplant / / Organization Food and Drug Administration / American Association for the Study of Liver Diseases / North American Society for Pediatric Gastroenterology / Hepatology and Nutrition Practice Guidelines / Food and Drug Administration Center / Infectious Diseases Society of America / Drug Evaluation Research office of Antimicrobial Products Division / FDA Antiviral Drugs Advisory Committee / / / Position infectious diseases physician / or liver transplant physician / infectious diseases physician / liver transplant physician / / Product Copegus / ribavirin / Olysio™ capsules / Pegasys / peginterferon / Sovaldi14 / QUEST-1 / QUEST-2 / / ProvinceOrState Florida / / Technology transplantation / genotype / / URL http / SocialTag 
PRIOR AUTHORIZATION POLICY Olysio™ (simeprevir capsules Janssen) To Initiate a Coverage Review, Call[removed]OVERVIEW Olysio is a hepatitis C virus (HCV) non-serine 3/4A (NS3/4A) protease inhibitor indicated for